IMCHECK THERAPEUTICS
ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
IMCHECK THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.imchecktherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+33 4 13 96 14 90
Total Funding:
172.93 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Pfizer Venture Investments
Pfizer Venture Investments investment in Series C - ImCheck Therapeutics
Eurazeo
Eurazeo investment in Series C - ImCheck Therapeutics
Life Sciences Partners
Life Sciences Partners investment in Series C - ImCheck Therapeutics
Wellington Partners
Wellington Partners investment in Series C - ImCheck Therapeutics
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series C - ImCheck Therapeutics
Bpifrance
Bpifrance investment in Series C - ImCheck Therapeutics
Pureos Bioventures
Pureos Bioventures investment in Series C - ImCheck Therapeutics
Invus
Invus investment in Series C - ImCheck Therapeutics
Leukemia & Lymphoma Society
Leukemia & Lymphoma Society investment in Series C - ImCheck Therapeutics
Earlybird Venture Capital
Earlybird Venture Capital investment in Series C - ImCheck Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-09 | ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer |
Official Site Inspections
http://www.imchecktherapeutics.com Semrush global rank: 8.75 M Semrush visits lastest month: 261
- Host name: vps144.geco-it.net
- IP address: 213.32.33.73
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "ImCheck Therapeutics"
Profile: Imcheck Therapeutics
Since its inception, ImCheck has gained the support of a syndicate of outstanding international funds. The Series C funding, bringing the total capital raised to more than USD 165 million, allows us to advance the clinical validation of First-in …See details»
ImCheck Therapeutics - LinkedIn
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.See details»
Investors - Imcheck Therapeutics
4 days ago Imcheck Therapeutics : Opening new spaces in Immuno-Oncology. Since its inception in 2015, ImCheck has raised approximately $85 million (Series A and B) from European and American equity investors to develop its unique …See details»
ImCheck Therapeutics - Crunchbase Company Profile …
ImCheck Therapeutics designs and develops immunotherapeutic antibodies for the treatment of cancer and autoimmune disease.See details»
Imcheck Therapeutics - Overview, News & Similar companies
Imcheck Therapeutics contact info: Phone number: +33 413961490 Website: www.imchecktherapeutics.com What does Imcheck Therapeutics do? Founded in 2015 and …See details»
ImCheck Therapeutics | Leukemia and Lymphoma Society
Jun 13, 2022 The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. Please check with your …See details»
Imcheck Therapeutics Company Profile | Management and
Www.imchecktherapeutics.com Imcheck Therapeutics Profile and History Founded in 2015 and headquartered in France, Imcheck Therapeutics designs and develops novel …See details»
ImCheck Therapeutics - Craft
ImCheck Therapeutics has 5 employees at their 1 location and $76.08 m in total funding,. See insights on ImCheck Therapeutics including office locations, competitors, revenue, financials, …See details»
ImCheck Therapeutics (France) Funding: €172.9M
5 days ago ImCheck Therapeutics is a privately-held French biotech company pioneering the next generation of immune checkpoint...See details»
ImCheck Therapeutics - PitchBook
ImCheck Therapeutics General Information Description. Developer of immuno-modulatory antibodies designed for treating cancer and other immune-related diseases. The company's antibodies offer next-generation …See details»
ImCheck Therapeutics - VentureRadar
Similar Companies: ImmunOs Therapeutics GmbH Switzerland Privately Held At ImmunOs Therapeutics AG, we have discovered a novel family class of therapeutics to explore ways to …See details»
ImCheck - EQT Group
Do You Want to Know More? We are eager to explore how we can achieve great things together.See details»
ImCheck Raises $53 Million Series B to Advance Clinical ... - Pfizer
Marseille, France, December 04, 2019, 7:30 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate gamma delta ( ) T cellsin a range of …See details»
Pipeline Overview - Imcheck Therapeutics
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology. Pipeline Overview Developing a broad pipeline of novel immunotherapeutic antibodies harnessing the innate & adaptive …See details»
ImCheck Therapeutics Company Overview, Contact Details
Aug 29, 2024 Nov 26, 2024 | www.imchecktherapeutics.com. ImCheck Therapeutics hired Stephan Braun as Chief Medical Officer on Jul 9th '24. Jul 09, 2024 | finance.yahoo.com. …See details»
Home | ImCheck Career
At ImCheck Therapeutics we value the uniqueness of each individual, and helping each person perform to the best of our abilities. We offer a wide number of development opportunities and …See details»
ImCheck Therapeutics - Seedtable
Track over 71,000 companies. Discover Fast-growing Global startups. Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.See details»
ImCheck Therapeutics once again recognized for its potential to …
May 22, 2024 ImCheck is a winner of the French Tech 120 program for the 5th year in a row and a winner of the new French Tech 2030 program announced nearly a year ago.See details»
ImCheck Announces Oral Presentation of Updated ICT01
5 days ago ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025. Marseille, France, April 23, 2025 10:00 a.m. ET / …See details»
News: Imcheck Therapeutics
Mar 25, 2025 Marseille, France, April 23, 2025 10:00 a.m. ET / 4:00 p.m. CET– ImCheck Therapeuticsannounced today an oral…See details»